Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs

The enhanced tumor specificity of TG6002, an armed-oncolytic vaccinia virus deleted in two genes involved in nucleotide metabolism

(2019) Johann Foloppe et al.   Molecular Therapy-Oncolytics

Optimizing oncolytic virotherapy in cancer treatment

(2019) Kevin Harrington et al.   NATURE REVIEWS DRUG DISCOVERY

Remission of spontaneous canine tumors after systemic cellular viroimmunotherapy

(2018) Teresa Cejalvo et al.   CANCER RESEARCH

Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma

(2018) Amy MacNeill et al.   Viruses-Basel

Oncolytic Viruses for Canine Cancer Treatment

(2018) Diana Sánchez et al.   Cancers

Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development

(2018) Daniel Regan et al.   ILAR JOURNAL

Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer

(2017) Shruthi Naik et al.   MOLECULAR CANCER THERAPEUTICS

Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours

(2017) C. C. Hwang et al.   Veterinary and Comparative Oncology

Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery

(2017) Dana Haddad   Frontiers in Oncology

Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers

(2016) Stephanie Downs-Canner et al.   MOLECULAR THERAPY

Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1

(2016)   Veterinary and Comparative Oncology

Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma

(2015) Che-Hsuan Kung et al.   BMC CANCER

Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles

(2015) Karoliina P. M. Autio et al.   BMC Veterinary Research

Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients

(2015) Timothy P Cripe et al.   MOLECULAR THERAPY

First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity

(2015) Herbert J Zeh et al.   MOLECULAR THERAPY

Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles

(2014) Karoliina Autio et al.   Molecular Therapy-Oncolytics

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

(2013) H. R. Ashbee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma

(2013) Sara Westberg et al.   JOURNAL OF IMMUNOTHERAPY

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

New viruses for cancer therapy: meeting clinical needs

(2013) Tanner S. Miest et al.   NATURE REVIEWS MICROBIOLOGY

Safety Studies on Intravenous Administration of Oncolytic Recombinant Vesicular Stomatitis Virus in Purpose-Bred Beagle Dogs

(2013) Amy K. LeBlanc et al.   Human Gene Therapy Clinical Development

Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients

(2012) Sandeep S. Patil et al.   Journal of Translational Medicine

1258 POSTER Phase I Clinical Trial of a Genetically Modified Oncolytic Vaccinia Virus GL-ONC1 With Green Fluorescent Protein Imaging

(2011) A. Biondo et al.   EUROPEAN JOURNAL OF CANCER

A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma

(2011) Tae-Ho Hwang et al.   MOLECULAR THERAPY

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

Dog models of naturally occurring cancer

(2011) Jennie L. Rowell et al.   TRENDS IN MOLECULAR MEDICINE

Long-lasting stability of Vaccinia virus strains in murine feces: implications for virus circulation and environmental maintenance

(2009) Jônatas S. Abrahão et al.   ARCHIVES OF VIROLOGY

Comparative expression pathway analysis of human and canine mammary tumors

(2009) Paolo Uva et al.   BMC GENOMICS

Efficient Adenovector CD40 Ligand Immunotherapy of Canine Malignant Melanoma

(2009) Henrik von Euler et al.   JOURNAL OF IMMUNOTHERAPY

Cancer Incidence in Pet Dogs: Findings of the Animal Tumor Registry of Genoa, Italy

(2009) D.F. Merlo et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY

Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: An investigation of potential fomites in the home environment

(2008) Edith Lederman et al.   VACCINE